



COMBINING TO CURE[®]

Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer.

CORPORATE PRESENTATION

January 2024

ARCUS
BIOSCIENCES

Forward-looking Statements/Safe Harbor

This presentation contains forward-looking statements about Arcus Biosciences, Inc. (“we,” “Arcus” or the “Company”) made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in the future contained in this presentation are forward-looking statements, including statements about: our strategy, advantages, and expectations, including regarding our productivity and competitiveness; expectation that our cash and investments are sufficient to fund operations into 2027; potential of our investigational products and portfolio; anticipated benefits of our collaborations with Gilead, Taiho and AstraZeneca; achievement and expected timing of clinical and developmental milestones, including completion of enrollment and presentation of clinical data; and possible first to market advantage for any of our investigational products. These forward-looking statements are subject to a number of risks, uncertainties and assumptions that may cause actual results to differ materially from those contained in any forward-looking statements we may make, including, but not limited to: risks associated with preliminary or interim clinical data or preclinical data not being guarantees that future data will be similar; the unexpected emergence of adverse events or other undesirable side effects; difficulties or delays in initiating, conducting or completing our clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials, all of which may be exacerbated by unfavorable global economic, political and trade conditions; risks associated with our collaboration arrangement with Gilead including our dependence on Gilead for the successful development and commercialization of our investigational products; changes in the competitive landscape; our limited operating history and our ability to manage our growth; risks regarding our license and collaboration agreements and our ability to obtain and maintain intellectual property protection for our product candidates; and the inherent uncertainty associated with pharmaceutical product development and clinical trials.

We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially and adversely from those anticipated or implied in the forward-looking statements. Further information on these and other factors that could affect the forward-looking statements made herein are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission.

You should not rely upon forward-looking statements as predictions of future events. Except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.

All of Arcus’s molecules are investigational and Arcus (and Gilead for all of the molecules in each optioned program) has not received approval from any regulatory authority for any use globally, nor established the safety and efficacy of these investigational molecules.

The Arcus name and logo are the property of Arcus. All other trademarks used herein are the property of their respective owners and are used for reference purposes only. Such use should not be construed as an endorsement of Arcus.

Arcus Has Created a Late-stage Portfolio of Differentiated Assets, Fueled by a Highly Productive R&D Engine

FUNDING INTO 2027

~\$1.2B in pro forma cash, cash equivalents & marketable securities*

LATE-STAGE COMPANY

Line of sight to first product approval (dom/zim)

2 new programs entering Phase 3 development by early 2025 (quemli, AB521)

MULTIPLE PHASE 3 STUDIES FOR DOM IN LUNG & UPPER GI

 STAR-121
  STAR-221
  STAR-131
 full enrollment expected in '24



MULTIPLE DATASETS IN 2024

Dom (TIGIT)

- EDGE-Gastric ASCO oral presentation

AB521 (HIF-2α)

- Dose escalation data
- Dose expansion data (2L+ ccRCC)

Quemli (CD73) / Etruma (A2R)

- ✓ ARC-8 (quemli) mature OS data at ASCO GI
- ARC-9 (etruma in CRC) PFS & OS results in 1H24

TOP TIER PARTNERS

Provides funding and resources enabling a diversified pipeline



TAIHO PHARMA



WORLD CLASS DRUG DISCOVERY

1-2 new development candidates a year

AB801

Initiated Phase 1/1b for potential best-in-class small molecule AXL inhibitor in Jan-24

2L: second-line; B: billion; ccRCC: clear cell renal cell carcinoma; dom: domv analimab; etruma: etrumadenant; GI: gastrointestinal; OS: overall survival; PFS: progression-free survival; quemli: quemlielustat; R&D: research and development; zim: zimberelimab

* = unaudited cash, cash equivalents and marketable securities of \$866M as of December 31, 2023 adjusted to give effect to equity investment by Gilead of \$320M in January 2024

Gilead Equity Investment and Portfolio Prioritization Enables Funding of Multiple Phase 3 Programs

EQUITY INVESTMENT

- **\$320mm investment** at \$21.00 per share
- Increases Gilead's ownership to 33%, **further aligning the two companies**
- **Funds Arcus into 2027**, through multiple late-stage datasets

DOMVANALIMAB PRIORITIZATION

- Closure of ARC-10 enables Arcus/Gilead to **focus on studies targeting the largest market opportunities** and unmet need
- **6 Phase 2 and 3 studies are ongoing in NSCLC and Upper GI cancers**
- **New Phase 3 (STAR-131) and a Phase 2 study to be initiated** in settings where we have the potential to be 1st to market

ADVANCEMENT OF QUEMLI AND AB521

- AB521 advancing rapidly with **datasets in 2024** and a planned **Phase 3 initiation by early 2025**
- **Phase 3 planning underway for quemli** in 1L pancreatic cancer

Arcus Has a Broad Portfolio of Investigational Molecules with Best-in-Class Potential Targeting Huge Market Opportunities



DIFFERENTIATED ANTI-TIGIT + ANTI-PD-1 BACKBONE

domvanalimab: Potential best-in-class, Fc-silent anti-TIGIT antibody – multiple ongoing Phase 2 and 3 studies in NSCLC and Upper GI cancers

zimberelimab: Anti-PD-1 antibody; approved in China for classical Hodgkin Lymphoma (cHL) and cervical cancer*



DIFFERENTIATED SMALL MOLECULES

AB521: Potential best-in-class HIF-2 α inhibitor; Phase 1/1b and Phase 2 studies in cancer patients are ongoing

quemliclustat: First-in-class small-molecule CD73 inhibitor; generated evidence of survival advantage in pancreatic cancer; cohort enrolling in NSCLC

etrumadenant: First-in-class dual A_{2a}R / A_{2b}R antagonist; generated evidence of clinical activity in colorectal cancer



NEXT-GENERATION PROGRAMS

AB801: Potential best-in-class small molecule AXL inhibitor; Phase 1/1b study in cancer patients is ongoing

AB598: Anti-CD39 antibody; Phase 1/1b study in cancer patients ongoing

KIT inhibitor: In preclinical evaluation

Four additional research programs in oncology and inflammation as part of the research collaboration with Gilead

WORLD-CLASS DRUG DISCOVERY

NSCLC: non-small cell lung cancer

*Gloria Biosciences secured China approvals; it holds commercial rights to zimberelimab in China and conducts its activities independently from Arcus

Three Late-Stage Programs with Multiple Upcoming Milestones; Earlier-Stage Portfolio Maturing

Program	Disease	Study	Line & Regimen	Ph 1/1b	Ph 2	Ph 3	Upcoming Milestones
Dom (Fc-silent anti-TIGIT antibody)	NSCLC	STAR-121	1L, PD-L1 all-comers, metastatic <u>dom</u> + zim + chemo vs pembro + chemo	[Progress bar]			• 2024: Enrollment completion
		STAR-131	Lung cancer	[Progress bar] PLANNED			• YE2024 / Early 2025: Ph 3 initiation
		PACIFIC8	Stage 3: durva ± <u>dom</u>	[Progress bar]			
		EDGE-Lung	1L / 2L, all-comers: <u>dom</u> +/- zim +/- quemli +/- chemo	[Progress bar]			
		VELOCITY-Lung	1L/2L NSCLC: <u>dom</u> ± zim ± etruma ± SG	[Progress bar]			• 2024: Initial data
	Upper GI	STAR-221	1L Upper GI Malignancies dom + zim + chemo vs. nivo + chemo	[Progress bar]			• 2024: Enrollment completion
	EDGE-Gastric	1L / 2L Upper GI Malignancies dom +/- zim +/- quemli +/- FOLFOX	[Progress bar]			• 1H2024: ASCO presentation	
AB521 (HIF2a inhibitor)	RCC	TBD	Not disclosed	[Progress bar] PLANNED			• Early 2025: Ph 3 initiation
		STELLAR ⁰⁰⁹	2L ccRCC: AB521 + zanza	[Progress bar]			
		ARC-20	all-comer cancer; 2L+ ccRCC AB521 monotherapy	[Progress bar]			• Early 2024: Dose escalation data • 2H24: Dose expansion data (30 pts, 6m+ follow-up)
ADENOSINE	PDAC	TBD	1L quemli + G/nP vs. GnP	[Progress bar] PLANNED			• YE2024 / Early 2025: Ph 3 initiation
		ARC-8	1L: quemli + zim + G/nP vs quemli + G/nP	[Progress bar]			✓ Jan 2024: Mature OS • 1H24: MORPHEUS-PDAC (etruma); mature PFS/OS
	CRC	ARC-9	2L: etruma + zim + FOLFOX vs FOLFOX 3L: etruma + zim + FOLFOX vs rego	[Progress bar]			• 1H24: Mature PFS/OS data in 3L
AB801 (Axl inhibitor)	STK-11m NSCLC	ARC-27	2L: AB801 ± chemo + zim	[Progress bar]			

1L: first line; 2L: second line; 3L: third line; ccRCC: clear cell renal cell carcinoma; dom: domv analimab; durva: durv alumab; etruma: etrumadenant; GI: gastrointestinal; G/nP: gemcitabine/nab-paclitaxel; NSCLC: non-small cell lung cancer; PD: pharmacodynamic; pembro: pembrolizumab; PFS: progression-free survival; Ph: phase; PK: pharmacokinetic; OS: overall survival; rego: regorafenib; SG: Sacituzumab; quemli: quemliclustat zanza; zanzalintinib; zim: zimberelimab

Our Partnerships Greatly Expand & Accelerate Opportunities Inherent in Arcus's Portfolio



10-YEAR "ALL-IN" COLLABORATION

- Over \$1.7b in non-dilutive payments and equity investments from Gilead
- Gilead has opted into 5 molecules to date -- shares costs for studies within the joint development plan
- Arcus retains U.S. co-commercial rights



COLLABORATION FOR JAPAN AND OTHER TERRITORIES IN ASIA (EX-CHINA)

- Up to \$275mm in development, regulatory and commercial milestones per program
- Tiered royalties from high-single digit to mid-teens on net sales



CLINICAL COLLABORATION FOR DOMVANALIMAB PLUS DURVALUMAB

- Companies collaborating on PACIFIC-8, a Phase 3 registrational trial sponsored by AstraZeneca
- Leverages AstraZeneca's leadership in the curative-intent Stage 3 NSCLC setting with funding shared
- Retained economics on respective molecules



CLINICAL COLLABORATION FOR AB521 + ZANZALINTINIB

- Companies collaborating on STELLAR-009, a Phase 1b/2 trial sponsored by Exelixis
- Potential to create a "best-in-class" TKI/HIF2 α combination
- Enables cost-effective path for development

ENABLES MULTIPLE "SHOTS ON GOAL" AND FUNDING INTO 2027

The background of the slide is a dark blue field filled with numerous microscopic images of cells. These cells are depicted with intricate, glowing internal structures in shades of cyan, magenta, and yellow, suggesting a focus on cellular biology or cancer research. The cells vary in size and complexity, with some showing more defined membranes and others appearing as dense clusters of fibers or organelles.

Domvanalimab in Non-Small Cell Lung Cancer and Upper GI Cancers

Domvanalimab, an Fc-Silent anti-TIGIT

DOMVANALIMAB

Most clinically advanced Fc-silent anti-TIGIT antibody in development

ZIMBERELIMAB

Anti-PD-1 antibody; approved in China (by Gloria*)

Dom may have important differences over Fc-enabled anti-TIGIT competitors

- ✓ **Peripheral T_{reg} numbers do not decrease** with dom + zim, but they do with Fc-enabled anti-TIGIT antibodies¹
- ✓ **No increase in irAEs** reported with dom + zim in ARC-7, in contrast to results from Fc-enabled anti-TIGIT antibodies which show higher incidences of rash, pruritis and infusion site reactions²

dom: domvanalimab; etruma: etrumadenant; irAE: immune-related adverse events; NSCLC: non-small cell lung cancer; zim: zimberelimab

* Gloria obtained approval for zim in China and conducts its activities independently from Arcus.

¹Gauthier, K. et al; Immunology 2022 (#2719): Anti-TIGIT Antibodies Promote Immune Activation Relevant to Targeting Stem-like and Tumor-specific T Cells in Combination With Anti-PD-1

²Johnson et al. Abstract 397600, ASCO 2023; data cut-off of Feb. 7, 2023

Two De-Risking Phase 2 Datasets for Domvanalimab-Containing Regimens Were Presented in 2023



1L Gastric/EAC/GEJ

dom + zim + FOLFOX (n=40)

ASCO Plenary Series

2024 ASCO
ANNUAL MEETING

- PD-L1-high (TAP $\geq 5\%$) for DZ + FOLFOX*:
 - **ORR/cORR: 80% / 73%**
 - **6-month PFS rate: 93%**
- Efficacy overall for DZ + FOLFOX*:
 - **ORR/cORR: 59%**
 - **6-month PFS rate: 77%**
- Incidence of adverse events was similar to prior experience with anti-PD-1 + FOLFOX



1L PD-L1 high NSCLC









dom + zim vs. zim vs. etruma + dom + zim (n=150)

2023 ASCO
ANNUAL MEETING

- PFS HRs:
 - **0.67** for DZ vs. Z
 - **0.72** for EDZ vs. Z
- ORRs or DZ and EDZ vs. Z
 - **Up to 14% improvement** in ORR
 - **Lower incidence** of progressive disease
- Similar rates of immune-related adverse events observed for DZ and Z – including rates of infusion-related reactions, rash and pruritis

*STAR-221 is evaluating PD-L1 High and all-comer populations with dual primary endpoints for PFS and OS
1L: first-line; D/dom: domvanalimab; EAC: esophageal adenocarcinoma; E/etruma: etrumadenant; GEJ: gastroesophageal junction; HR: hazard ratio; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; TAP: tumor area positivity; Z/zim: zimberelimab
EDGE-Gastric - Janjigian et al. ASCO Plenary Series, Nov. 7, 2023; data cut off of Sept. 4, 2023
ARC-7 Johnson et al. Abstract 397600, ASCO 2023; data cut-off of Feb. 7, 2023

Phase 3 Program for Dom is Targeting Significant Market Opportunities

STUDY	LEAD SPONSOR	SETTING	US PATIENT POPULATION ¹
 STAR-121	 GILEAD	1L NSCLC, PD-L1 All comers	119k patients
 STAR-131	 GILEAD	NSCLC	TBA
 PACIFIC-8	 AstraZeneca	Stage 3 NSCLC	21k patients
 STAR-221	 ARCUS BIOSCIENCES	1L Gastric/GEJ/EAC	25k patients

Multi-billion revenue opportunities for Arcus / Gilead

\$10B+ addressable market¹


1L: first-line; B: billion; EAC: esophageal adenocarcinoma; GEJ: gastroesophageal junction;; K: thousand' NSCLC: non-small cell lung cancer; TBA: to be announced
¹Based on expected drug treatable US patient population. Excludes patients with actionable mutations.
 Source: Decision Resources Group.
 Adenos: adenocarcinoma; dom: domv analimab; GEJ: gastroesophageal junction;

Summary of EDGE-Gastric Arm-A1 Results and Domvanalimab Clinical Program in Upper GI Cancers

Data presented at the November 2023 ASCO Plenary Series, based on data cut off of September 4, 2023.

Phase 2 Trial to Evaluate Dom- and Zim-based combos in Advanced Upper GI Malignancies


ARMS NOT RANDOMIZED, ENROLLED SEQUENTIALLY



1L: first-line; 2L: second-line; CPI: checkpoint inhibitor; DCR: disease control rate; dom: domv analimab; DOR: duration of response; EAC: esophageal adenocarcinoma; ECOG: Eastern Cooperative Oncology Group; GEJ: gastroesophageal junction; IV: intravenous; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; PK: pharmacokinetics; quemli: quemliclustat; QxW: every x weeks; RECIST: Response Evaluation Criteria in Solid Tumors; zim: zimberelimab

Janjigian et al. ASCO Plenary Series, Nov. 7, 2023; data cut off of Sept. 4, 2023

Results for Arm A1 in 1L Metastatic Gastric/GEJ/EAC Were Presented at ASCO Plenary in November 2024



At the 4 September 2023 data cutoff, the minimum follow up was 6 months.

1L first-line; DCR: disease control rate; dom: domv analimab; DOR: duration of response; EAC: esophageal adenocarcinoma; ECOG: Eastern Cooperative Oncology Group; GEJ: gastroesophageal junction; ORR: objective response rate; OS: overall survival; PD: progressive disease; PFS: progression-free survival; PK: pharmacokinetics; QxW: every x weeks; RECIST: Response Evaluation Criteria in Solid Tumors; zim: zimberelimab

Janjigian et al. ASCO Plenary Series, Nov. 7, 2023; data cut off of Sept. 4, 2023

Promising ORR and 6-Month PFS Results

- As of the 4 September 2023 data cutoff, 24 patients (59%) continued on study treatment

	PD-L1 High* (TAP ≥5%) N=15 n (%)	PD-L1 Low* (TAP <5%) N=24 n (%)	Efficacy-Evaluable N=41 n (%)
ORR, % [95% CI]	80 [52, 96]	46 [26, 67]	59 [42, 74]
Confirmed ORR, % [95% CI]	73 [45, 92]	46 [26, 67]	56 [40, 72]
Confirmed Complete Response	1 (7)	0	2 (5)
Confirmed Partial Response	10 (67)	11 (46)	21 (51)
Unconfirmed Partial Response [†]	1 (7)	0	1 (2)
Stable Disease	3 (20)	10 (42)	14 (34)
Progressive Disease	0	2 (8)	2 (5)
No Post-Baseline Scan	0	1 (4)	1 (2)


CI: confidence interval; ITT: intent to treat; ORR: objective response rate; TAP: tumor area positivity

*Tumor samples from 39 patients were available for central PD-L1 testing.

[†]One partial response was not confirmed and the patient has discontinued study treatment as of the data cutoff.

Janjigian et al. ASCO Plenary Series, Nov. 7, 2023; data cut off of Sept. 4, 2023

Almost All Patients Experience Some Benefit, Irrespective of PD-L1 Status





*MSI-high

Landmark 6-Month PFS Compares Favorably to Benchmark Data of 60-65%; Median PFS Still Immature


Efficacy-Evaluable (N=41)
6-month PFS = 77%

PD-L1 High (TAP $\geq 5\%$, N=15)
6-month PFS = 93%



Safety Profile is Similar to FOLFOX Alone

TEAE	Arm A1 N=41, n (%)
Any TEAE	41 (100)
TEAEs related to any study drug	40 (98)
Grade ≥3 TEAEs	28 (68)
Grade ≥3 TEAEs related to any study drug	23 (56)
Serious TEAEs	10 (24)
Serious TEAEs related to any study drug	2 (5)
TEAEs leading to permanent withdrawal from any study drug	20 (49)
TEAEs leading to dose modification/interruption of any study drug	33 (81)
TEAEs resulting in death	0



ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TEAE: treatment-emergent adverse event

*'Neutrophil count decreased', 'Neutropenia', and 'Febrile neutropenia' were coded to separate Preferred Terms and combined post-hoc.

Janjigian et al. ASCO Plenary Series, Nov. 7, 2023; data cut off of Sept. 4, 2023

© Arcus Biosciences 2024

Phase 3 Evaluating Dom + Zim + Chemo vs Nivo + Chemo in 1L Gastric, GEJ and Esophageal Adenocarcinoma

KEY ELIGIBILITY CRITERIA:

- 1L locally advanced unresectable or metastatic w/o prior systemic treatment
- Measurable disease (RECIST 1.1)
- PD-L1 all comers
- Known HER-2 positive tumors excluded

Stratification Factors:

- PD-L1 expression (TAP $\geq 5\%$ or TAP $< 5\%$)
- ECOG PS (0 or 1)
- Region (US/Canada/EU5 vs. Asia vs. rest of world)

N=970

R
1:1

domvanalimab + zimberelimab + PI
choice of chemo*

nivolumab + PI choice of chemo*

No crossover or change of
chemotherapy allowed

DUAL PRIMARY ENDPOINTS:

- OS ITT
- OS in TAP $\geq 5\%$

KEY SECONDARY ENDPOINTS:

- PFS ITT
- PFS in TAP $\geq 5\%$

★ Initiated in 3Q22

1L: first-line; dom: domvanalimab; ECOG: Eastern Cooperative Oncology Group; GEJ: gastroesophageal junction; nivo: nivolumab; ITT: intent to treat; OS: overall survival; PFS: progression-free survival; PI: principal investigator; RECIST: Response Evaluation Criteria in Solid Tumors; TAP: tumor area positivity (revised nomenclature for vCPS [visually-estimated composite positive score]); R: randomized; zim: zimberelimab

*PI choice of chemo: FOLFOX or CAPOX.


NCT #: NCT05568095

Janjigian et al. ASCO Plenary Series, Nov. 7, 2023; data cut off of Sept. 4, 2023

Summary of ARC-7 Results and Domvanalimab Clinical Program in Non-Small Cell Lung Cancer

Data presented at the 2023 ASCO Annual Meeting, based on data cut off of Feb. 7, 2023.

Randomized, Open-label, Ph2 Study in First-Line, Metastatic, PD-L1-High NSCLC



Participants randomized to Arm 1 had the option to crossover to separate, 2L EDZ cohort upon radiographically confirmed disease progression (PD)

- As of the clinical cut-off date (Feb. 7, 2023), a total of 150 patients were randomized, with a median follow-up of 18.5 months

ADA: anti-drug antibody; D/dom: domv analimab; ECOG: Eastern Cooperative Oncology Group; E/etruma: etrumadenant; IV: intravenous; NSCLC: non-small cell lung cancer; ORR: overall response rate; Ph: phase; PFS: progression-free survival; PK: pharmacokinetics; PO: orally; R: randomized; RECIST: Response Evaluation Criteria in Solid Tumors; Z/zim: zimberelimab; Q3W: every 3 weeks; QD: once-daily


Johnson et al. Abstract 397600, ASCO 2023; data cut-off of Feb. 7, 2023

Dom-containing Arms Improved ORRs vs Zim Monotherapy

- Across all arms, one patient in the DZ arm had a pending partial response that was confirmed after data cut-off date
- Subjects ongoing treatment with stable disease have potential to contribute to objective response rate with further data maturity

ITT, % (n)	Z (n=50)	DZ (n=50)	EDZ (n=50)
ORR, confirmed + pending [95% CI]	30% (15) [18, 45]	40% (20) [26, 55]	44% (22) [30, 59]
Complete Response	2% (1)	2% (1)	0% (0)
Partial Response – confirmed	28% (14)	36% (18)	44% (22)
Partial Response – pending	0% (0)	2% (1)	0% (0)
Stable Disease	32% (16)	36% (18)	32% (16)
Progressive Disease	24% (12)	8% (4)	14% (7)
Not evaluable	14% (7)	16% (8)	10% (5)

Addition of Dom to Zim Resulted in a 33% Reduction in Risk of Progression or Death, Compared to Zim Monotherapy




Overall Safety Profile

ITT, % (n)	ARM 1 (Z) (n=50)	ARM 2 (DZ) (n=50)	ARM 3 (EDZ) (n=50)
Any TEAEs	100% (50)	98% (49)	98% (49)
Grade ≥3 TEAE	64% (32)	46% (23)	60% (30)
Grade 5, Related to Study Treatment*	2% (1)	2% (1)	4% (2)
Serious TEAE	56% (28)	34% (17)	52% (26)
TEAEs leading to study drug discontinuation	28% (14)	18% (9)	18% (9)
Immune-related TEAE	48% (24)	50% (25)	66% (33)
Infusion-related Reactions	4% (2)	4% (2)	12% (6)
Median Treatment Duration, weeks (range)	16.9 (0, 103)	26.2 (0, 130)	36.1 (2, 130)

- Most common TEAEs (≥15% overall): nausea, fatigue, constipation, dyspnea, pneumonia, decreased appetite and diarrhea
- Grade ≥3 events occurring in ≥5% of patients: pneumonia (12%) and anemia (7%)
- *Related Grade 5 TEAEs: interstitial lung disease (Arm 1), myocarditis (Arm 2), pneumonitis (Arm 3), and congestive heart failure (Arm 3)

Phase 3 Evaluating Dom + Zim + Chemo vs. Pembro + Chemo in 1L NSCLC (All PD-L1 Subgroups)

- Uses standard of care, pembrolizumab, in the comparator arm



Strat Factors:

- Baseline PDL1 PD-L1 status (≥50% vs. 1-49%)
- Geography (east Asia vs non-east Asia)
- Histology (Sq vs Non-sq)

★ **Initiated in 3Q22**


1L: first-line; BICR: blinded independent central review; dom: domv analimab; DOR: duration of response; ECOG: Eastern Clinical Oncology Group; NSCLC: non-small cell lung cancer; ORR: objective response rate; OS: overall survival; pembro: pembrolizumab; PFS: progression-free survival; QoL: quality of life; R: randomized; sq: squamous; zim: zimberelimab

Gilead Sciences is operationalizing STAR-121

NCT #: NCT05502237

Phase 3 Evaluating Dom + Durva vs Placebo + Durva in Unresectable, Stage III NSCLC

- Combines domvanalimab (dom) with durvalumab (durva) standard-of-care in Stage III NSCLC
- Potential to be first anti-TIGIT combination in this curative intent setting



Strat Factors:

- Disease stage prior to cCRT (IIIA vs. IIIB/IIIC)
- PD-L1 status (TC $\geq 50\%$ vs. TC 1-49%), as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay
- Histology (Sq vs Non-sq)

CD73-Adenosine Axis Programs



Quemliclustat in Pancreatic Cancer


Quemliclustat (quemli): A Unique, Highly Potent and Selective Small Molecule CD73 Inhibitor with Several Key Advantages

QUEMLICLUSTAT

- Highly potent molecule
- Target coverage achieved at doses as low as 25 mg every two weeks
- Extremely long (4+ days) half-life, enabling Q2W dosing by IV infusion

Biological rationale for CD73 inhibition in pancreatic cancer

Pancreatic cancer exhibits very high expression levels of CD73



mRNA Levels from analysis of The Cancer Genome Atlas (TCGA)

Potential advantages over CD73 antibodies¹

- ✓ Highly potent and selective inhibition of both tumor cell-bound and soluble CD73
- ✓ Greater inhibition of enzymatic production of adenosine
- ✓ Orders of magnitude more potent
- ✓ Greater permeability of tumor tissue

Q2W: every 2 weeks

quemliclustat is an investigational molecule and its safety and efficacy have not been established.

1) Arcus Biosciences data on file

Final Overall Survival Analysis for Quemli in Pancreatic Cancer (ARC-8)

Data presented at ASCO GI, January 19, 2024, based on a data cutoff of June 19, 2023.

Highlights from the ARC-8 Study in 1L PDAC

Median overall survival (mOS) was 15.7 months for patients treated with a quemliclustat-based regimen, which exceeds the historical benchmark data for chemotherapy alone (8.5 – 11.7 months)^{1,2}

A 37% reduction in risk of death and a 5.9-month improvement in mOS was observed for patients treated with the quemli-based regimen when compared to a synthetic control arm of patients treated with G/nP alone¹

The quemli-based regimen was well-tolerated, with no new safety signals or significant added toxicity compared to chemotherapy alone¹

Phase 3 planning is underway


1L first-line; G/nP: gemcitabine/nab-paclitaxel; PDAC: pancreatic ductal adenocarcinoma; quemli: quemliclustat

1. Wainberg ZA, et al. ASCO GI, Jan. 19, 2024, data cut off of June 19, 2023

2. Abraxane USPI, 2020 and Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272-1281. doi:10.1016/S0140-6736(23)01366-1

© Arcus Biosciences 2024

ARC-8 Study Design Included Dose Escalation, Expansion and Randomized Portions



Safety monitoring throughout treatment period; radiographic disease evaluation every 8 weeks. Study treatment continued to disease progression, unacceptable toxicity, consent withdrawal, or investigator decision.

1L: first-line; 2L: second-line; IV: intravenously; G/nP: gemcitabine/nab-paclitaxel; mPDAC: metastatic pancreatic ductal adenocarcinoma; PDAC: pancreatic ductal adenocarcinoma; Q2W: every 2 weeks; Q/quemli: quemli; R: randomization; RDE: recommended dose for expansion; Z/zim: zimberelimab
 NCT #: NCT04104672

Dataset Includes Four Groups of Patients Treated with 100 mg of Quemli

Cohort	Quemli Dose	Combination	Participants Dosed	>18m OS f/u?	Population
Dose escalation	25 mg	Q + Z + G/nP (quad)	4	Yes	1L mPDAC
Dose escalation	50 mg	Q + Z + G/nP (quad)	6	Yes	1L mPDAC
Dose escalation	75 mg	Q + Z + G/nP (quad)	3	Yes	1L mPDAC
Dose escalation	100 mg	Q + Z + G/nP (quad)	6	Yes	1L mPDAC
Cohort A	100 mg	Q + Z + G/nP (quad)	26*	Yes (except for 3)*	1L mPDAC
Cohort A1 (randomized)	100 mg	Q + Z + G/nP (quad)	61	Yes	1L mPDAC
Cohort A2 (randomized)	100 mg	Q + G/nP (triplet)	29	Yes	1L mPDAC
Dose escalation	125 mg	Q + Z + G/nP (quad)	3	Yes	1L mPDAC

93 Pooled Q100 quad
122 Pooled Q100 All

1L: first-line; f/u: follow up; G/nP: gemcitabine/nab-paclitaxel; mPDAC: metastatic pancreatic ductal adenocarcinoma; OS: overall survival; Q/quemli: quemliclustat; Z/zim: zimberelimab

3 additional patients enrolled as contemporaneous control for Cohort C

Wainberg ZA, et al. ASCO GI, Jan. 19, 2024, data cut off of June 19, 2023

Demographics And Baseline Characteristics Are Well Balanced Across Arms & Efficacy-evaluated Populations

% ECOG 1 (65%-69%) Was Higher than Historical G/nP Studies (42-57%); % Liver Mets (59%-69%) Was Slightly Lower than Historical G/nP Studies (78-85%) – See Slide 36 for OS Results

% (n)	A2: Q + G/nP (n=29)	A1: QZ + G/nP (n=61)	Pooled Q100 QZ + G/nP (n=93)	All Pooled Q100 Q ±Z)+G/nP (n=122)	
Median Age (IQR)	65.0 (61, 70)	66.0 (58, 72)	66.0 (58, 72)	65.5 (59, 72)	
Age ≥65	55 (16)	59 (36)	58.1 (54)	57.4 (70)	
Female	48 (14)	49 (30)	47 (44)	48 (58)	
Race	White	83 (24)	74 (45)	74 (69)	76 (93)
	Asian	6.9 (2)	8.2 (5)	8.6 (8)	8.2 (10)
	Black	3.4 (1)	6.6 (4)	5.4 (5)	4.9 (6)
	Other/NR	6.9 (2)	11 (7)	12 (11)	11 (13)
ECOG 0	31 (9)	30 (18)	34 (32)	34 (41)	
ECOG 1	69 (20)	69 (42)	65 (60)	66 (80)	
ECOG Missing	-	1.6 (1)	1.1 (1)	0.8 (1)	
Liver Metastasis at Baseline¹	58.6 (17)	68.9 (42)	66.7 (62)	64.8 (79)	


ECOG: Eastern Cooperative Oncology Group; G/nP: gemcitabine/nab-paclitaxel; IQR: interquartile range; NR: not reported; Q: quemiclustat; Z: zimberelimab

1. Derived from baseline tumor assessment data

Wainberg ZA, et al. ASCO GI, Jan. 19, 2024, data cut off of June 19, 2023

© Arcus Biosciences 2024

With 21-month Median Follow-up, OS Results Exceed Ph3 Benchmarks for G/nP



Phase 3 G/nP median OS Benchmarks^{1,2}
8.5 – 11.1 months

	Number of patients at risk																
	0	2	4	6	8	10	12	14	16	18	20	22	24	26	28	30	32
A2: Q+G/nP	29	28	26	23	20	19	16	15	14	12	9	3	0	0	0	0	0
A1: QZ+G/nP	61	53	48	40	31	29	27	23	20	13	9	4	2	1	0	0	0
Pooled Q100 QZ+G/nP	93	84	77	66	53	50	43	35	30	22	18	12	8	4	2	1	0
All pooled Q100 Q(±Z)+G/nP	122	112	103	89	73	69	59	50	44	34	27	15	8	4	2	1	0

NE, not estimable; OS, overall survival; Q, quomiclustat; Z, zimborelimab.

CI: confidence interval; G/nP: gemcitabine/nab-paclitaxel; Ph3: Phase 3
 1. Abraxane USPI, 2020 and Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272-1281. doi:10.1016/S0140-6736(23)01366-1
 2. Von Hoff et al. N Engl J Med 2013;369:1691-703.
 Wainberg ZA, et al. ASCO GI, Jan. 19, 2024, data cut off of June 19, 2023

Favorable OS for Patients With & Without Liver Metastasis

- Because ARC-8 had a lower incidence of liver mets than historical studies, we analyzed the OS for ARC-8 patients with and without liver mets as shown below
- When adjusting for the lower incidence of liver mets in the triplet arm, mOS for the triplet and quad arms looked almost identical at approx. 12 months
- **When evaluating just those patients with liver mets, median OS still exceeded historical benchmarks AND meaningfully outperformed the OS for patients with liver mets in NAPOLI-3 (the most contemporary phase 3 in 1L pancreatic) -- 12.1 mos for ARC-8 vs. 8.6 mos for NAPOLI-3**

Liver Mets at Baseline	A2: Q + G/nP (n=17)	A1: QZ + G/nP (n=42)	Pooled Q100 QZ + G/nP (n=62)	All Pooled Q100 Q(±Z) + G/nP (n=79)	NAPOLI-3 (n=309)
Events (%)	11 (64.7)	26 (61.9)	40 (64.5)	51 (64.6)	242 (78.3)
Median OS, months	12.1	12.2	11.1	12.1	8.6
95% CI	10.0, 20.9	6.2, 17.9	8.1, 14.5	10.0, 15.7	

No Liver Mets at Baseline	A2: Q + G/nP (n=12)	A1: QZ + G/nP (n=19)	Pooled Q100 QZ + G/nP (n=31)	All Pooled Q100 Q(±Z) + G/nP (n=43)	NAPOLI-3 (n=78)
Events (%)	4 (33.3)	7 (36.8)	16 (51.6)	20 (46.5)	43 (55.1)
Median OS, months	22.0	21.2	21.2	21.5	13.8
95% CI	17.9, NE	14.6, NE	13.9, 25.4	17.9, 25.4	

BL: Baseline; CI: confidence interval; G/nP: gemcitabine/nab-paclitaxel; mets: metastasis; mOS: median overall survival; mos: months; NE: not estimable; OS: overall survival; Q: quemiclustat

NAPOLI-3: Wainberg, et al. *The Lancet*. Sept 2023. [https://doi.org/10.1016/S0140-6736\(23\)01366-1](https://doi.org/10.1016/S0140-6736(23)01366-1). Data shown is for the G/nP arm only

Wainberg ZA, et al. ASCO GI, Jan. 19, 2024, data cut off of June 19, 2023

© Arcus Biosciences 2024

Safety Profile Similar to G/nP with Regards to Overall TEAEs

%	A2: Q + G/nP (n=29)	Pooled Q100 QZ + G/nP (n=93)	All Pooled Q100 Q ±Z)+G/nP (n=122)	NAPOLI-3 G/nP Benchmark ⁴ (n=379)
Any TEAE	100	100	100	99
Any TRAE	100	98.9	99.2	93
Grade 3-5 TEAE	89.7	83.9	85.2	86
Grade 3-5 TRAE	75.9	72.0	73.0	68
Serious TEAE	51.7	53.8	53.3	52
Serious TRAE	34.5	25.8	27.9	19
Grade 5 TEAE	0	5.4	4.1	6
Grade 5 TRAE	0	0	0	2
AE leading to mod ¹	58.6	51.6	53.3	54
AE leading to dose delay	75.9	75.3	75.4	NR
AE leading to discon ²	24.1	22.6	23.0	23
IRR ²	10.3	6.5	7.4	N/A
Immune related AE ³	6.9	10.8	9.8	N/A

AE: adverse event; G/nP: gemcitabine/nab-paclitaxel; IRR: infusion-related reaction; NA: not applicable; NR: not reported; TEAE: treatment-emergent adverse event; TRAE: treatment-related adverse event


1. AE leading to dose reduction; 2. Discontinuation of any study drug; 3. As reported by investigator; 4. Wainberg, et al. The Lancet. Sept 2023. [https://doi.org/10.1016/S0140-6736\(23\)01366-1](https://doi.org/10.1016/S0140-6736(23)01366-1)

Wainberg ZA, et al. ASCO GI, Jan. 19, 2024, data cut off of June 19, 2023

Arcus & Medidata AI Synthetic Control Arm (SCA) Project

- Developed in collaboration with Medidata, the industry's leading provider of electronic data capture for clinical trials
- Constructed SCA using historical data from patients treated with G/nP alone and balanced to the patient baseline characteristics of ARC-8
 - Contemporaneous global randomized Phase 2 and 3 clinical trials that meet key ARC-8 entry criteria
 - 515 eligible external patients identified for further matching
 - SCA matched to All Pooled Q100 Q±Z+G/nP (n=122) using propensity score statistical method including exact matching on baseline liver metastasis
- Assessed the treatment effects on OS, PFS, and objective response rate in the SCA patients and compared these to the matched ARC-8 patients
- **SCA analyses were conducted versus all four analysis groups and showed consistent results**; for simplicity, only the SCA for the All Pooled Q100 group was reported

Quemli-based Regimen Significantly Reduced Risk of Death by 37% and increased mOS by 5.9 months



	Number of patients at risk														
	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42
All pooled Q100 Q(±Z)+G/nP	122	108	89	72	59	47	34	23	8	3	1	0			
SCA	122	104	85	61	49	32	26	21	12	7	4	3	1	0	

--- Median Follow-up, All pooled Q100 Q(±Z)+G/nP

G/nP, gemcitabine/nab-paclitaxel; OS, overall survival; Q, quemli; SCA, synthetic control arm; Z, zimerelimab.



Etrumadenant in Colorectal Cancer

Etrumadenant Represents a Potentially Best-in-Class Adenosine Receptor Antagonist

ETRUMADENANT


- Highly potent small molecule that inhibits both the A2aR and A2bR receptors
- Excellent penetration of tumor tissue and drug properties (PK, etc.)
- **Data from ARC-9 evaluating etruma + zim + chemo vs. regorafenib in 3L CRC is expected to be presented in 1H:24**

Etruma has ideal pharmacological properties

- ✓ Retains potency in physiologically relevant conditions
 - $IC_{50} = 87nM$
- ✓ High tumor penetration
 - Tumor: Plasma ratio: >60%
- ✓ Low CNS permeability (in mouse model)
 - ~1% of the concentration found in blood
- ✓ Full engagement of target across dosing time period in humans
 - $\geq 90\%$ target inhibition at trough

Randomized Phase 2 Study to Evaluate Etruma Combinations in 3L+ mCRC

- Randomized Phase 2 study evaluating etruma + zim + chemo combinations vs. SOC in 2L/3L mCRC
- **Mature PFS / OS data for Cohort B (3L) expected to be presented in 1H24 (n=105)**
- Cohort A (2L) results are still immature



1H: first half; 2L: second-line; 3L: third-line; bev: bevacizumab; etruma: etrumadenant; irino: irinotecan; mCRC: metastatic colorectal cancer; OS: overall survival; oxali: oxaliplatin; PFS: progression-free survival; R: randomized; SOC: standard of care; zim: zimberelimab

*bev will be included for all patients in whom it is not contraindicated

NCT #: NCT04660812

HIF-2 α Program

Value Proposition for AB521, a Potential Best-in-Class, HIF-2 α Inhibitor

Potency

Opportunity to reach greater intra-tumoral HIF-2 α inhibition compared to 120 mg dose of belzutifan

- Requires a compound with greater potency and/or a better PK/PD profile than belzutifan
- Potentially without increased toxicity, which appears to be driven by peripheral (normal tissue) on-target effects that saturate at lower doses


Novel Combinations

Opportunity to create potentially best-in-class and first-in-class combinations

- Announced clinical collaboration with Exelixis to combine AB521 with their next-generation TKI, zanzalintinib


Extensive Preclinical Characterization Confirms Greater Potency of AB521 Relative to that of Belzutifan (MK-6482)

	ASSAY	AB521	MK-6482 ^a
CELLULAR	HIF-2α 786-O Luc Reporter IC ₅₀ (nM)	8.2 ± 2.5 (n=24)	16.9 ± 10.1 (n=8)
	Control 786-O Luc Reporter IC ₅₀ (nM)	> 10,000 (n=6)	> 10,000 (n=7)
	HIF-2α 786-O Luc Reporter IC ₅₀ (nM) [in 100% Serum]	46.5 ± 14.2 (n=24)	61.8 ± 6.6 (n=4)
	786-O VEGF AlphaLISA IC ₅₀ (nM)	28.9 ± 3.6 (n=11)	47.7 ± 30.8 (n=4)
BIOCHEMICAL	HIF-2α TSAT _m Δ (°C)	14.7 ± 0.6 (n=14)	12.1 ± 0.3 (n=4)
	HIF-2α MST K _D (nM)	2.4 ± 0.8 (n=3)	15.4 ± 2.7 (n=3)
	HIF-2α ITC K _D (nM)	53.6 ± 17.9 (n=3)	53.8 ± 19.3 (n=3)
	HIF-2α SPA IC ₅₀ (nM)	16.6 ± 5.0 (n=8)	22.3 ± 5.6 (n=5)




AB521 is a HIF-2 α Inhibitor with Best-in-Class PK-PD Properties

20 mg of AB521 achieves near-complete EPO suppression (peripheral PD marker for HIF2 α inhibition) - while a 120mg dose of belzutifan (the approved dose) is required for this level of EPO suppression



Human PK profile of AB521 Increases in a dose-linear fashion
Daily 100 mg AB521 expected to provide ~5x more drug to the tumor than the reference drug



EPO: erythropoietin; PD: pharmacodynamics; PK: pharmacokinetics

§ AB521: Observation (points) and median (solid line) and inter-quartile range (shaded area) of pop PK/PD simulations

‡ Source: Belzutifan NDA - FDA review document

© Arcus Biosciences 2024

AB521 Monotherapy Dose Escalation/Expansion in ccRCC is Ongoing

PH 1 DOSE ESCALATION

3+3 design with 21-day DLT window **Solid-tumor patients w/o SOC**

KEY INCLUSION CRITERIA

- At least 1 measurable lesion per RECIST 1.1
- Adequate organ and marrow function
- ccRCC (in dose expansion)

KEY EXCLUSION CRITERIA

- No prior HIF-2α inhibitor (dose expansion only)



CURRENT STATUS:


- Dose escalation enrolled 12 patients; 4 of whom had ccRCC plus 2 who had non-ccRCC and were treated at the 50mg QD or 50mg BID doses. Safety/PK/PD/anecdotal efficacy data to be presented early 2024
- **Enrollment of the dose expansion cohort evaluating the 100 mg daily dose (n=30) completed in November 2023 – results to be shared 2H:24**

Phase 1b/2 Study of AB521 + Zanzalintinib +/- Nivolumab in Advanced Solid Tumors Including ccRCC*

DOSE FINDING

DOSE EXPANSION

* Potential multiple additional cohorts of ~6 patients each, guided by BOIN DLT rules



1L: first-line; 2L: second-line; ccRCC: clear cell renal cell carcinoma; DOR: duration of response; nivo: nivolumab; ORR: objective response rate; OS: overall survival; PK: pharmacokinetics; Q4W, every 4 weeks; RD: recommended dose; zanza: zanzalintinib

*STELLAR-009 is being operationalized by Exelixis

AXL Program

AXL Signaling is a Common Mechanism of Resistance to Chemotherapy and Immunotherapy in Tumors

THERAPEUTIC HYPOTHESIS:

AXL inhibition will overcome multiple mechanisms of drug-resistance


Cancer Cell Intrinsic

- Pro-survival signaling
- Increased DNA damage repair
- Increased EMT
- Decreased MHC-I & activating immune ligands
- Increased PD-L1 & immunosuppressive cytokines


Cancer Cell Extrinsic

- Decreased DC function & T-cell activation / infiltration
- Increased M2 macrophage & T-reg activation
- Increased paracrine AXL/ Gas6 signaling in the TME

AXL signals via Ligand-dependent and Ligand-independent mechanisms



AB801 sensitizes cancer cells to chemotherapy




AB801 is a Potent, Selective, and Efficacious AXL Inhibitor

AB801 is a highly potent and selective AXL inhibitor

Assay		AB801
BIOCHEMICAL	AXL K_i	0.024 nM
	Fold selectivity over hMERTK/ hTYRO3 (enzyme K_i over AXL K_i)	860x / 1400x
	Kinome Selectivity against 403 kinases at 100x IC_{50} for AXL	Only one kinase with less than 200x fold selectivity
CELLULAR	pAXLELISA IC_{50} (serum-free media)	17 nM
	pAXLELISA IC_{50} (100% serum)	68 nM

Combination of AB801 with Oxaliplatin & α -PD-1 Increases Anti-Tumor Efficacy and Survival in Preclinical Models*



- Vehicle
- OXA
- OXA + PD-1
- AB801 + OXA
- AB801
- PD-1
- AB801 + PD-1
- AB801 + OXA + PD-1




AB801 is Believed to be the Most Potent & Selective AXL Inhibitor in Clinical Development

THERAPEUTIC HYPOTHESIS: Inhibiting AXL will overcome resistance against chemotherapy and immunotherapy in human tumors

- AB801 was designed to potently and selectively inhibit AXL signaling in tumors, resulting in enhanced responses to chemotherapy and immunotherapy
 - Other “AXL inhibitors” may not be potent enough or lack selectivity (leading to toxicity) that may limit their use at doses suitable for efficient AXL inhibition
- Phase 1 study in Healthy Volunteers is ongoing:
 - No safety issues have been observed to date in the first 3 dose-escalation cohorts
 - Pharmacokinetics were dose-proportional and appear to support once-daily dosing
- Phase 1 study (ARC-27) in patients with advanced solid tumors is underway; **Two expansion cohorts planned:**
 - STK-11 mutant NSCLC
 - 2L NSCLC

APPENDIX


Domvanalimab (dom): Most Advanced Fc-Silent TIGIT Antibody in Clinical Development




TIGIT is another checkpoint receptor expressed on immune cells that binds CD155 on tumor cells, leading to further evasion of anti-tumor immunity

Dom is an investigational molecule designed to block TIGIT, enable CD155:CD226 interaction and immune cell activation
 Combined inhibition of TIGIT and PD1 may have a synergistic effect, unleashing immune activity against certain tumor cells


AB521 in the Cancer Cell Nucleus



The CD73-Adenosine Axis Plays a Well-Established and Critical Role in Suppression of the Immune Response



Platform Design to Rapidly Evaluate Novel Combinations for NSCLC, Including Quemli and Dom-based Regimens



The image features several decorative virus-like particles (VLPs) in the corners. They are rendered in a light blue and white color scheme, showing a textured, spherical surface. One is in the top right, one in the bottom left, and one in the bottom right.

ARCUS

BIO SCIENCES

COMBINING TO CURE[®]